Skip to content
Subscriber Only

Merck KGaA Raises Forecast as Quarterly Profit Tops Estimate

  • 2015 sales, profit forecast boosted after including Sigma
  • Sales of top-selling Rebif almost unchanged in third quarter
Updated on

Merck KGaA, Germany’s second-largest publicly traded pharmaceutical company, posted third-quarter profit that beat analysts’ estimates and raised its forecast for the year following the $17 billion acquisition of specialty chemical firm Sigma-Aldrich Corp.

A measure of earnings excluding some costs and one-time items rose 10 percent to 944 million euros ($1.02 billion), the Darmstadt, Germany-based company said in a statement Thursday. That’s higher than the 919 million-euro average of nine estimates compiled by Bloomberg. The shares rose to the highest in more than three months.